

Title: Durable Responses in Patients with Synovial Sarcoma in the Phase I Trial of ADP-A2M4 (MAGE-A4)

Authors: Brian A. Van Tine, David S. Hong, Melissa L. Johnson, David Liebner, Kunle Odunsi, Trupti Trivedi, Quan Lin, Swethajit Biswas, Erica Elefant, Jean-Marc Navenot, Joana Senra, Zohar Wolchinsky, Robyn Broad, Gareth Betts, Natalie Bath, Will Spinner, Alex Tipping, Svetlana Fayngerts, Karen Miller, Amy Sun, Dennis Williams, Paula M. Fracasso, Elliot Norry, Marcus O. Butler

Background: This trial (NCT03132922) evaluated safety, tolerability, and antitumor activity of ADP-A2M4, genetically engineered autologous specific peptide enhanced affinity receptor (SPEAR) T-cells directed towards a MAGE-A4 peptide in patients (pts) with multiple solid tumor malignancies. Herein, follow-up data from pts with advanced synovial sarcoma is presented (n=16). The main portion of this trial is closed for enrollment, a low-dose radiation sub-study remains open.

Methods: This Phase I dose-escalation, expansion trial evaluated HLA-A*02 positive (excluding *02:05) pts with advanced cancers expressing MAGE-A4. Autologous T-cells were isolated, transduced with a lentiviral vector containing the MAGE-A4^{c1032} TCR, and expanded. Prior to infusion, pts received lymphodepletion with cyclophosphamide and fludarabine. Cohorts 1, 2, 3, and Expansion were to receive transduced cell doses of up to: 0.12×10^9 , 1.2×10^9 , 6×10^9 , and 10×10^9 , respectively. Disease was assessed per RECIST v1.1 by CT/MRI at wks 6, 12, 18, and 24, and every 3 months for 2 years, then every 6 months or until disease progression.

Results: As of Apr 2020, 16 pts with advanced synovial sarcoma were treated in either Cohort 3 or Expansion with a median transduced cell dose of 8.86×10^9 (range: 3.41 to 9.97×10^9). Median age was 49.0 yrs (range: 31 to 76) and median H-score of MAGE-A4 expression was 248.5 (range: 60.4 to 300). All pts received prior chemotherapy (median 2.5 regimens, range 1 to 6). Most common (>30%) AEs \geq Grade 3 were lymphopenia, leukopenia, neutropenia, anemia, thrombocytopenia, hypophosphatemia, and febrile neutropenia. Cytokine release syndrome (any grade) was reported in 13 pts (81%); the majority was Grade 1 or 2 (11 pts). One pt with synovial sarcoma had a Grade 5 SAE, (76-yr-old female; aplastic anemia) leading to modification of the lymphodepletion regimen and eligibility criteria. The Overall Response Rate was 44% and the Best Overall Response was PR (7), SD (7), PD (1), and pending (1). Responses were durable (median duration approximately 28 wks (range: 12 to 54⁺ wks [PR at 54 wks ongoing])). Median OS had not been reached. SPEAR T-cells were detectable in peripheral blood and tumor tissue, and responded to antigen in vitro. Increases in T-cell infiltration, MHCI, and PD-L1 expression were observed in post-infusion tumor biopsies of some responding pts. Higher MAGE-A4 levels were associated with greater tumor reduction.

Conclusions: ADP-A2M4 induced clinical responses in pts with synovial sarcoma and had an acceptable safety profile. Transduced T-cells persist in vivo and remain functional. Analyses to determine factors that may influence response remain ongoing. These data support the ongoing SPEARHEAD-1 trial (NCT04044768).